Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | TST | Q16762 | 2/20 | 0.83 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.83 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | USP2 | O75604 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | HAT1 | O14929 | 4/20 | 0.74 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | RECQL | P46063 | 3/20 | 0.74 |
| ▸ | CASP7 | P55210 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CASP1 | P29466 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin 5'-Phosphate SCHEMBL297863 | 1.00 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL41133 | 1.00 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL1532396 | 1.00 | ESR1 (1.00) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL6681480 | 0.99 | ESR1 (0.98) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL29592831 | 0.96 | ESR1 (0.93) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL14571231 | 0.94 | ESR1 (0.89) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL19864293 | 0.94 | ESR1 (0.88) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL11995383 | 0.94 | ESR1 (0.88) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| SCHEMBL3402467 | 0.93 | ESR1 (0.86) | ESR1NR3C1ADRB2HTR2CADRA1A | |
| Riboflavin 5'-Phosphate SCHEMBL8656633 | 0.92 | TST (0.98) | ESR1NR3C1ADRB2HTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1776 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744677-A1 | DRY EYE DISEASE TREATMENT THROUGH PHOTOSENSITIZER | Universitatea de Medicina, Farmacie, Stiinte si Tehnologie "George Emil Palade" din Targu Mures (RO) | 2026-05-20 | — | — | EP | claimed |
| US-20260131002-A1 | METHOD OF TREATMENT | QUEENSLAND EYE INST FOUNDATION (AU) | 2026-05-14 | — | — | US | claimed |
| US-20260131004-A1 | METHOD OF TREATMENT OR INHIBITION | QUEENSLAND EYE INST FOUNDATION (AU) | 2026-05-14 | — | — | US | claimed |
| EP-4739312-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS Therapeutics LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-12419860-B2 | Time release sleep aid system | NIGHTWISE, LLC (US) | 2025-09-23 | — | — | US | claimed |
| US-20250249035-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH OXIDATIVE STRESS | CXL OPHTHALMICS LLC (US) | 2025-08-07 | — | — | US | claimed |
| EP-4019646-B1 | METHODS AND KITS FOR DETECTING SPERM DNA FRAGMENTATION | BONRAYBIO CO LTD (TW) | 2025-06-11 | — | — | EP | claimed |
| EP-4537831-A2 | PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D, SUITABLE FOR THE TREATMENT AND/OR PROPHYLAXIS OF DISORDERS OF THE BONE METABOLISM AND THERAPY-INDUCED SIDE EFFECTS SUCH AS HYPOCALCEMIA | Karl, Christoph (CH) | 2025-04-16 | — | — | EP | claimed |
| US-20250093260-A1 | DEVICES, SYSTEMS, AND METHODS FOR AGROCHEMICAL DETECTION AND AGROCHEMICAL COMPOSITIONS | SPOGEN BIOTECH INC. | 2025-03-20 | — | — | US | claimed |
| WO-2025034554-A9 | COMPOSITIONS AND METHODS FOR DELIVERY OF OPHTHALMOLOGICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-03-13 | — | — | WO | claimed |
| EP-0336214-B1 | PROCESS FOR THE PURIFICATION OF SALTS OF RIBOFLAVIN-5'-MONOPHOSPHATE, ESPECIALLY MONOSODIUM-RIBOFLAVIN-5'-MONOPHOSPHATE | BASF Aktiengesellschaft (DE) | 1992-04-01 | — | — | EP | claimed |
| US-5095115-A | Phosphorylation, salt formation | BASF AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | claimed |
| EP-0417604-A2 | Process for preparing riboflavin-5'-phosphate and its sodium salt | BASF Aktiengesellschaft (DE) | 1991-03-20 | — | — | EP | claimed |
| US-4987229-A | Adsorption of riboflavin on macroreticular polymer | BASF AKTIENGESELLSCHAFT (DE) | 1991-01-22 | — | — | US | claimed |
| EP-0384366-A2 | Photosensitive recording element | BASF Aktiengesellschaft (DE) | 1990-08-29 | — | — | EP | claimed |
| EP-0364875-A1 | Riboflavin-4'5'-cyclo-phosphoric acid ester chloride, its preparation and use for the preparation of riboflavin-5'-phosphate (5'-FMN) or its sodium salt | BASF Aktiengesellschaft (DE) | 1990-04-25 | — | — | EP | claimed |
| WO-1989011544-A1 | RIBOFLAVIN-LINKED ASSAY PROCEDURES AND MATERIALS | LONDON BIOTECHNOLOGY LIMITED (GB) | 1989-11-30 | — | — | WO | claimed |
| EP-0336214-A1 | Process for the purification of salts of riboflavin-5'-monophosphate, especially monosodium-riboflavin-5'-monophosphate | BASF Aktiengesellschaft (DE) | 1989-10-11 | — | — | EP | claimed |
| US-4476304-A | Process for the purification of riboflavine-5'-monophosphate | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1984-10-09 | — | — | US | claimed |
| US-4213893-A | Flavin adenine dinucleotide-labeled conjugates for use in specific binding assays | MILES LABORATORIES, INC. (US) | 1980-07-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131004-A1 | METHOD OF TREATMENT OR INHIBITION | PPOX, PPID, PNPO | ESR1 3689/4885NR3C1 4612/4885ADRB2 2735/4885 |
| US-20260131002-A1 | METHOD OF TREATMENT | PPOX, P2RX5, PRDX1 | ESR1 1833/4885NR3C1 3825/4885ADRB2 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.